Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

57 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of the Bruton's Tyrosine Kinase Inhibitor Evobrutinib in Systemic Lupus Erythematosus: Results of a Phase II, Randomized, Double-Blind, Placebo-Controlled Dose-Ranging Trial.
Wallace DJ, Dörner T, Pisetsky DS, Sanchez-Guerrero J, Patel AC, Parsons-Rich D, Le Bolay C, Drouin EE, Kao AH, Guehring H, Dall'Era M. Wallace DJ, et al. Among authors: kao ah. ACR Open Rheumatol. 2023 Jan;5(1):38-48. doi: 10.1002/acr2.11511. Epub 2022 Dec 18. ACR Open Rheumatol. 2023. PMID: 36530019 Free PMC article.
Characterisation of the safety profile of evobrutinib in over 1000 patients from phase II clinical trials in multiple sclerosis, rheumatoid arthritis and systemic lupus erythematosus: an integrated safety analysis.
Montalban X, Wallace D, Genovese MC, Tomic D, Parsons-Rich D, Le Bolay C, Kao AH, Guehring H. Montalban X, et al. Among authors: kao ah. J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):1-9. doi: 10.1136/jnnp-2022-328799. Epub 2022 Nov 23. J Neurol Neurosurg Psychiatry. 2023. PMID: 36418156 Free PMC article. Clinical Trial.
Disease trajectory of SLE clinical endpoints and covariates affecting disease severity and probability of response: Analysis of pooled patient-level placebo (Standard-of-Care) data to enable model-informed drug development.
Goteti K, French J, Garcia R, Li Y, Casset-Semanaz F, Aydemir A, Townsend R, Mateo CV, Studham M, Guenther O, Kao A, Gastonguay M, Girard P, Benincosa L, Venkatakrishnan K. Goteti K, et al. CPT Pharmacometrics Syst Pharmacol. 2023 Feb;12(2):180-195. doi: 10.1002/psp4.12888. Epub 2022 Nov 29. CPT Pharmacometrics Syst Pharmacol. 2023. PMID: 36350330 Free PMC article.
Evolution of neuronal cell classes and types in the vertebrate retina.
Hahn J, Monavarfeshani A, Qiao M, Kao AH, Kölsch Y, Kumar A, Kunze VP, Rasys AM, Richardson R, Wekselblatt JB, Baier H, Lucas RJ, Li W, Meister M, Trachtenberg JT, Yan W, Peng YR, Sanes JR, Shekhar K. Hahn J, et al. Among authors: kao ah. Nature. 2023 Dec;624(7991):415-424. doi: 10.1038/s41586-023-06638-9. Epub 2023 Dec 13. Nature. 2023. PMID: 38092908 Free PMC article.
The ALPHA Project: Establishing consensus and prioritisation of global community recommendations to address major challenges in lupus diagnosis, care, treatment and research.
Tse K, Sangodkar S, Bloch L, Arntsen K, Bae SC, Bruce IN, Connolly-Strong E, Costenbader KH, Dickerson B, Dörner T, Evans S, Kalunian K, Kao AH, Manzi S, Morand EF, Raymond SC, Rovin BH, Schanberg LE, Von Feldt JM, Werth VP, Williams Derricott A, Zook D, Franson T, Getz K, Peña Y, Hanrahan LM; ALPHA Project Global Advisory Committee. Tse K, et al. Among authors: kao ah. Lupus Sci Med. 2021 Feb;8(1):e000433. doi: 10.1136/lupus-2020-000433. Lupus Sci Med. 2021. PMID: 33563729 Free PMC article.
57 results